Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about symptoms and gastrointestinal lesions
associated with taking myfortic® by switching patients to a delayed release formulation that
is developed to alleviate GI symptoms. A comparison of the frequency and severity of GI
symptoms observed in patients treated with MMF (cellcept®) after conversion to myfortic® will
be measured by using a self-assessed questionnaire called Gastrointestinal Symptom Rating
Scale (GSRS). To prove the incidence and improvement of GI lesions in patients treated with
MMF (cellcept®) after conversion to myfortic® will be measured by using Small Bowel Capsule
Endoscopy (SBCE).